Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 2/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7433359 | 0.85 | CYP2A6 (0.53) | CYP2A6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1444688 | 0.84 | CYP2A6 (0.51) | CYP2A6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1444757 | 0.81 | CYP2A6 (0.59) | CYP2A6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL17209265 | 0.80 | EPHX1 (0.49) | CYP2A6HDAC3HDAC1HDAC2ADRB2 | |
| SCHEMBL17209264 | 0.80 | MAPT (0.50) | MEN1USP2POLBBLMKMT2A | |
| SCHEMBL793123 | 0.78 | HDAC3 (0.47) | CYP2A6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL17209262 | 0.78 | TRPV1 (0.47) | MEN1KMT2A | |
| SCHEMBL17209263 | 0.77 | CASR (0.54) | HDAC1RAB9AMEN1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL4499713 | 0.77 | CYP2A6 (0.50) | CYP2A6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14756368 | 0.74 | CYP2A6 (0.69) | CYP2A6ADRB2ASIC3LOXL2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2558474-B1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2501705-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8642593-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8618095-B2 | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130150329-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8389515-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2558474-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2501705-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20110124599-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2011063241-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2010147898-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
| US-20100041678-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20090306028-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| EP-1951261-A4 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS INC (US) | 2009-06-24 | — | — | EP | disclosed |
| EP-1951261-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117775-A1 | Compositions and Methods For Treating Inflammatory Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2007053844-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041678-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | SYK, IRAK2, IRAK4 | CYP2A6 4145/4885HDAC3 1374/4885HDAC4 1364/4885 |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | CYP2A6 4178/4885HDAC3 3004/4885HDAC4 2483/4885 |
| US-20110124599-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | DPYD, TYMP, PNP | CYP2A6 434/4885HDAC3 2855/4885HDAC4 2469/4885 |
| US-20130150329-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | DPYD, TYMP, PNP | CYP2A6 434/4885HDAC3 2855/4885HDAC4 2469/4885 |
| US-20090306028-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | SYK, IRAK2, IRAK4 | CYP2A6 4226/4885HDAC3 1177/4885HDAC4 1264/4885 |
| US-20070117775-A1 | Compositions and Methods For Treating Inflammatory Disorders | SYK, IRAK2, IRAK4 | CYP2A6 4226/4885HDAC3 1177/4885HDAC4 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.